Use of axitinib, a new-generation tyrosine kinase inhibitor, to decrease glioblastoma growth despite primary resistance to the VEGF-antibody bevacizumab.
Tobias Kratzsch
No relevant relationships to disclose
Viktor Gruenwald
No relevant relationships to disclose
Peter Vajkoczy
No relevant relationships to disclose
Susanne Antje Kuhn
No relevant relationships to disclose